Ricevi le ultime notizie sulle azioni Gilead Sciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di GILD

Ultime notizie per

GILEAD SCIENCES INC

Gilead Sciences

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Alphabet

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

GILD

GOOG

GOOGL

INTC

Divergenze nel tech dopo le trimestrali: buyback e dividendi spingono un titolo, guidance debole penalizza un produttore di chip.

Azioni chiave da monitorare oggi sul mercato USA: focus su GOOG e INTC

Fort,Lauderdale,,Fla - usa,-,April,15,,2017:,Cnbc,Trademark,Emblem

Media

AMZN

KLAC

Wall Street svela le carte. Un&#39;analisi sui titoli che attirano l&#39;attenzione degli investitori e dei professionisti del settore.

&#34;Final Trades&#34;: le 4 azioni consigliate dai migliori esperti di Wall Street

ALAB

HLIT

Performance trimestrali imminenti, previsioni degli analisti e possibili sorprese: quali titoli si distingueranno in questa giornata?

Coca-Cola, Marriott e altre 3 azioni da tenere d&#39;occhio oggi

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

Gilead Sciences Announces Second Quarter 2025 Financial Results

Gilead Sciences to Present at Upcoming Investor Conferences

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Genmab

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Gilead Sciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO